NASDAQ:TVGNW Tevogen Bio (TVGNW) Stock Price, News & Analysis $0.05 +0.01 (+11.88%) As of 03:33 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock About Tevogen Bio Stock (NASDAQ:TVGNW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.03▼$0.15Volume66,189 shsAverage Volume104,981 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing. The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors. Tevogen Bio has advanced multiple candidate therapies into preclinical studies and early-phase clinical trials, evaluating safety, dosing strategies and preliminary efficacy across diverse patient populations. Originating from translational immunology research at the Sheba Medical Center in Israel, Tevogen Bio secured exclusive rights to novel TCR technologies and subsequently established operations in the United States. The company completed a corporate transaction to become publicly listed on the Nasdaq under the ticker TVGNW, positioning it to accelerate clinical development and expand manufacturing capabilities. Headquartered in the United States, Tevogen Bio collaborates with leading academic institutions and clinical centers worldwide to optimize its T cell engineering processes and trial designs. The company’s leadership team combines expertise in cell therapy development, translational research and regulatory affairs with a shared commitment to delivering scalable immunotherapies for patients in need.AI Generated. May Contain Errors. Read More Receive TVGNW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVGNW Stock News HeadlinesTevogen Bio Holdings Inc. Outlines Strategic Growth and Advancements in AI-Driven Healthcare SolutionsAugust 11, 2025 | quiverquant.comQTevogen Bio Holdings Inc. Secures $1 Million Funding to Advance Tevogen.AI Drug Discovery InitiativeAugust 7, 2025 | quiverquant.comQTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.October 16 at 2:00 AM | Porter & Company (Ad)Tevogen Bio Holdings Inc. Secures $1 Million Grant to Advance AI-Driven Drug Discovery InitiativeAugust 1, 2025 | quiverquant.comQTevogen Bio Grants Restricted Stock to CEOJuly 10, 2025 | tipranks.comTevogen Bio Holdings Enters $50M Sales AgreementJuly 3, 2025 | tipranks.comSee More Headlines TVGNW Stock Analysis - Frequently Asked Questions How have TVGNW shares performed this year? Tevogen Bio's stock was trading at $0.0540 at the beginning of 2025. Since then, TVGNW stock has decreased by 3.3% and is now trading at $0.0522. How do I buy shares of Tevogen Bio? Shares of TVGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:TVGNW CIK1860871 Webtevogen.com Phone877-838-6436FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TVGNW) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.